$7.6-billion Elanco deal gets FTC green lightJuly 15, 2020Elanco Animal Health has received unanimous approval for its $7.6-billion acquisition of Bayer’s animal health division.
SPONSORED CONTENTOne dose protects for 12 months.One ProHeart® 12 (moxidectin) injection puts compliance in your control. + Get started
Bayer, Pharamaron union to streamline drug developmentNovember 29, 2019A partnership between Bayer and life sciences R&D company, Pharamaron, aims to accelerate the production of innovative therapies to address the unmet medical needs of animal patients.
Bayer pledges $200k in domestic violence aidOctober 8, 2019A Bayer-sponsored grant program that aims to support victims of domestic violence by ensuring the safety of their pets has received an extra boost.
Elanco acquires Bayer's animal health division in $7.6-billion dealAugust 20, 2019Following months of speculation, two major industry players have finalized a deal, resulting in the creation of the second-largest animal health company in the world.
Bayer and Elanco rumored to be mergingJuly 10, 2019A significant animal health merger might be in the works between pharmaceutical company Bayer and Elanco Animal Health.
Bayer Animal Health, Nutreco to enhance nutritional health of farm animalsMay 21, 2019Bayer Animal Health and Nutreco are combining their efforts to improve the nutritional and health performance of farm animals. The companies have signed a global research and development collaboration agreement. Their first project together will be to come up with innovative solutions for gastrointestinal health in dairy and beef cattle. "The agreement further demonstrates our strong commitment to drive innovation in the farm animal space," says Douglas Hutchens, DVM, PhD, Bayer's head of drug discovery, external innovation and chief veterinary officer. "Joining forces with Nutreco will increase our innovative capabilities and leverage the development of new solutions for our customers. We look forward to furthering farm animal health and well-being, and contributing to the sustainable development of the dairy and beef cattle industry." The project will be run by Trouw Nutrition. "We're excited to be partnering with a company like Bayer to bring real breakthroughs in this area," says Trouw Nutrition innovation director, Saskia Korink. "By pooling our know-how and capabilities, we can truly make significant steps forward and support farmers in growing their business in a sustainable way with animal well-being as a priority."
Bayer, adivo to develop therapeutic antibodiesApril 17, 2019Bayer Animal Health and adivo have signed an agreement to develop therapeutic antibodies for companion animals. The collaboration may be good news for veterinary medicine. Although the use of therapeutic antibodies is not widespread, they offer a variety of healing options for diseases that still cannot be treated with current technology. "Today's agreement is another example of how we realize our innovation strategy," says Douglas Hutchens, DVM, PhD, Bayer Animal Health's head of drug discovery, external innovation and chief veterinary officer. "By combining the know-how from creative start-up companies like adivo with opportunities derived from Bayer's research, we broaden our space of therapeutic medicine options and complement our portfolio. We are constantly looking for innovative technologies enabling us to generate novel treatment options for the companion animal sector. Now, we will focus on evolving the options presented by adivo from research and development to market maturity." Under the terms of the agreement, Bayer will have access to adivo's species-specific monoclonal antibody technology, which uses an exclusive fully canine phage display library. Bayer will provide targets involved in severe animal diseases. "At adivo, we truly believe pets have a positive impact on our society," says the company's managing director, Kathrin …
Bayer to leave animal health marketDecember 7, 2018A longtime player in animal health care is leaving the industry. In 2019, Bayer Animal Health will make pharmaceuticals, consumer health, and crop science primary focus areas.
